Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELOQUENT-2: Elotuzumab with Lenalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT01239797Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2011
- Primary completion
- Sep 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 3 trial of elotuzumab in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Started Jun 2011; status: completed.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01239797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01239797.